Webinar: How to prepare for Affiliate-Based Outsourcing for Regulatory Affairs?
Affiliate-Based Outsourcing (ABO) Model for Regulatory Affairs works as a replacement or an extension of the company’s internal and local RA resources, which are often insufficient for the effective organization and execution of regulatory activities. The essential element for the successful implementation of the ABO model is the company’s readiness for this change. The purpose of this webinar is to share the key steps and practical tips on the preparation for Affiliate-Based Outsourcing for Regulatory Affairs.
Registering your MD in the EAEU?
- Milestones in the journey towards the Affiliate-Based Outsourcing
- Triggers and Reasons for the Regulatory Affairs ABO
- Preparation for the ABO
- Key elements you should consider while getting ready for the Regulatory Affairs ABO
Duration: 50 minutes
Speaker: Head of Regulatory Affairs, Olga Bernardova.
Olga Bernardova
Head of Regulatory Affairs
Other content that might interest you:
Effective IMPD Writing. The Quality Part
Webinar: Effective IMPD Writing. The Quality Part Effective IMPD writing, including the quality part is a vital document that contains information about an investigational medicinal product and it is an essential part of the Clinical Trial Application (CTA), which is...
Medical Device Registration in Russia. The Essentials
Webinar: Successful Medical Device Registration in Russia. The Essentials The current national system for Medical Device registration in Russia was created from scratch and entered into force in 2013. Most experts agree that this system is complex and puzzling – some...
Expediting access through Reliance Pathways: MENA region
Reliance models are review pathways used by Regulators to expedite the patient access to essential pharmaceutical products and to overcome resource constraints and priorities. Recently, several National Competent Authorities (NCA) in the Middle East North Africa (MENA) region have implemented the Abridged and Verification reviews. These regulatory procedures allow the approvement of needed innovative and/or life-saving drugs.
